768 related articles for article (PubMed ID: 34445310)
1. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
[TBL] [Abstract][Full Text] [Related]
2. Corilagin and 1,3,6-Tri-
Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
[TBL] [Abstract][Full Text] [Related]
3. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
5. Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.
Haddad M; Gaudreault R; Sasseville G; Nguyen PT; Wiebe H; Van De Ven T; Bourgault S; Mousseau N; Ramassamy C
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269785
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
Elife; 2020 Oct; 9():. PubMed ID: 33103998
[TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.
Maas MN; Hintzen JCJ; Löffler PMG; Mecinović J
Chem Commun (Camb); 2021 Apr; 57(26):3283-3286. PubMed ID: 33651072
[TBL] [Abstract][Full Text] [Related]
9.
Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
[TBL] [Abstract][Full Text] [Related]
10. The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target.
Al-Zaidan L; Mestiri S; Raza A; Merhi M; Inchakalody VP; Fernandes Q; Taib N; Uddin S; Dermime S
Tumour Biol; 2021; 43(1):177-196. PubMed ID: 34420993
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of molecular interaction, physicochemical parameters and conserved pattern of SARS-CoV-2 Spike RBD and hACE2: in silico and molecular dynamics approach.
Chakraborty C; Sharma AR; Mallick B; Bhattacharya M; Sharma G; Lee SS
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1708-1723. PubMed ID: 33629340
[TBL] [Abstract][Full Text] [Related]
12. In silico investigation of critical binding pattern in SARS-CoV-2 spike protein with angiotensin-converting enzyme 2.
Jafary F; Jafari S; Ganjalikhany MR
Sci Rep; 2021 Mar; 11(1):6927. PubMed ID: 33767306
[TBL] [Abstract][Full Text] [Related]
13. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
14. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis for higher affinity of SARS-CoV-2 spike RBD for human ACE2 receptor.
Delgado JM; Duro N; Rogers DM; Tkatchenko A; Pandit SA; Varma S
Proteins; 2021 Sep; 89(9):1134-1144. PubMed ID: 33864655
[TBL] [Abstract][Full Text] [Related]
16. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
[TBL] [Abstract][Full Text] [Related]
18. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
Kalathiya U; Padariya M; Fahraeus R; Chakraborti S; Hupp TR
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33671255
[TBL] [Abstract][Full Text] [Related]
19. Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles.
Lim K; Nishide G; Yoshida T; Watanabe-Nakayama T; Kobayashi A; Hazawa M; Hanayama R; Ando T; Wong RW
J Extracell Vesicles; 2021 Dec; 10(14):e12170. PubMed ID: 34874124
[TBL] [Abstract][Full Text] [Related]
20. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
